Parker Institute doubles down on cancer vaccines Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 14 April, 2026

AI has gone from buzzword to pipeline strategy — but are the results a mixed bag? We're talking to the researchers in the thick of it about what's moving the needle, what's stalling out and what comes next. Join us for a free virtual program, then continue the conversation at an in-person-only fireside and happy hour in Boston. Choose your pass.

presented by CNS-3D Brain Organoids Pre­dict Clin­i­cal Seizure Li­a­bil­i­ty, New Study Da­ta

news Parker Institute doubles down on cancer vaccines as part of ongoing reboot FDA approves Travere's Filspari as the first drug for a rare kidney disorder

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher

The R&D 15 is John Carroll’s annual reckoning with where biopharma’s biggest players are really investing — and where they’re not. This year he’s back at the table with some of the industry’s top research chiefs for a frank, one-hour conversation on the trends shaping drug development in 2026 and beyond. Join us.

ENDPOINTS PHARMA Exclusive: FDA narrows in on search for new biologics and vaccines leader White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says  Regeneron wades into radiopharma through $40M upfront deal with Telix

in case you missed it 1. Revolution Medicines' pancreatic cancer drug doubles survival time in Phase 3 2. Allogene’s first look at data on its ‘off-the-shelf’ CAR-T shows promise 3. News Briefing Neomorph raises $100M for molecular glues; Spyre's ulcerative colitis data 4. BioNTech's HER2 ADC succeeds in Phase 2 study, FDA filing planned 5. Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial 6. Strong early data prompts GSK to plan five Phase 3 studies for gynecological cancer ADC 7. Updated: Seaport and Hemab file for IPOs, as Kailera prices 8. FDA calls on drug developers to publish missing data from thousands of trials